ABCL Soars 35% on ABCL635 Phase 2 Hot Flash Data

AbCellera (ABCL) reported positive Phase 2 data for ABCL635 this morning, and the stock ripped 34.8% to $9.34. It closed Friday at $6.93. The market cap now sits at roughly $2.12 billion on volume of 46 million shares, more than 10x the daily average. Investors are betting that an antibody injected once a month can beat a daily pill.

The Phase 2 enrolled 92 postmenopausal women averaging about 10 moderate-to-severe hot flashes per day. A single subcutaneous 600 mg dose of ABCL635 cut daily VMS frequency by 83% from baseline at week 4, versus 33% for placebo, a 50% placebo-adjusted difference. Severity dropped 58% versus 12% for placebo, a 46% adjusted difference. Both endpoints hit statistical significance (p<0.001) by week 1 and held through week 4. Sleep scores and patient global impression of change also improved meaningfully. No serious adverse events, no severe AEs, and no discontinuations.

ABCL635 targets the neurokinin 3 receptor (NK3R) on KNDy neurons in the hypothalamus, the same mechanism that Astellas validated with Veozah (fezolinetant), FDA-approved in May 2023. But ABCL635 is an antibody, not a small molecule. That means monthly subcutaneous dosing instead of a daily pill, and a cleaner safety profile. Fezolinetant carries a liver safety warning; the FDA required baseline and monthly liver function monitoring before starting treatment. Bayer’s elinzanetant, another oral NK3R antagonist, is under FDA review and faces the same class scrutiny. ABCL635 showed no liver signals in this 92-patient Phase 2 readout.

The market opportunity is not subtle. Roughly 12 million US women experience moderate-to-severe vasomotor symptoms. Many cannot or will not take hormone therapy. Veozah generated $97 million in its first full year on the US market, a modest launch partly constrained by the liver monitoring requirement. A well-tolerated monthly injection without hepatic safety baggage could expand the addressable population meaningfully.

The risks are standard for a Phase 2 asset. The durability question, whether a single dose lasts a full month or a Phase 3 maintenance schedule requires more frequent dosing, won’t be answered until the Phase 2b/3 dose-ranging trial reads out. Immunogenicity is always a watch item with therapeutic antibodies. And Bayer’s elinzanetant, if approved, will be the second oral NK3R antagonist on the market before ABCL635 reaches registration.

AbCellera plans a Phase 2b/3 dose-ranging study next. The timeline and design were not in the morning press release, but the company hosts a conference call at 7:30 AM ET today. For a framework on parsing these readouts, see the guide to reading clinical trial press releases.

What It Means for the Trade

The 35% move on 46 million shares — more than 10x average volume — is the market repricing one specific thing: ABCL635’s potential to be the first non-oral entrant in a VMS market where the incumbents’ main friction is liver monitoring. Roughly $550 million of market cap was added on a 92-patient Phase 2, which means the market is now underwriting not just the mechanism but a Phase 3 program that has not been formally designed yet. That is the gap traders should respect: today’s price assumes the Phase 2b/3 reads out like this Phase 2 did, and Phase 2 VMS data has a well-documented history of compressing at scale as placebo responses and trial populations shift. The correct stance is not skepticism — the 50% placebo-adjusted efficacy split and the clean safety are real — but an awareness that the next data event is the one that matters.

The commercial thesis is genuinely differentiated, which is why the move was this large. Veozah’s $97 million first year is often read as evidence the market is modest; the better read is that it is evidence of what a launch with a liver-monitoring burden looks like. The ~12 million U.S. women with moderate-to-severe VMS is the denominator, and a monthly subcutaneous antibody with no hepatic signal removes the two biggest adoption frictions in the class: daily pill adherence and monthly-to-baseline liver function tests. Hormone therapy remains the entrenched default, but a meaningful population cannot or will not take it, and that is the population the NK3R class is actually fighting over — the women’s health stocks ranking covers why ABCL is the one pure play on that shelf.

Mechanism and Competitive Context

The target is validated and the format is the innovation. NK3R antagonism dampens the KNDy neuron circuit in the hypothalamus that drives the vasomotor reflex — Astellas proved the target with fezolinetant’s May 2023 approval, and Bayer’s elinzanetant is under FDA review as the second oral. AbCellera’s bet is that an antibody solves the class’s structural problem: small-molecule NK3R antagonists are dosed daily, distribute systemically, and carry hepatotoxicity baggage that the FDA has flagged within the class. A monoclonal avoids first-pass hepatic exposure entirely, which is the mechanistic reason ABCL635 can show no liver signal where orals cannot, and monthly dosing converts a chronic daily-pill adherence problem into a routine office-visit injection.

The competitive timeline is the risk timeline. Elinzanetant’s FDA decision lands before ABCL635 even starts Phase 3, which means AbCellera will enter a market with two approved orals — but both will carry the class’s liver-safety caveats, and neither will have an injection-schedule answer for the adherence-sensitive population. The real strategic question for AbCellera is positioning: does ABCL635 get developed as the premium, liver-safe option for patients failed by orals, or as a first-line mass-market play? The former is the faster label path; the latter is the bigger market and the harder Phase 3.

Risks and What Could Go Wrong

1. Durability is the unanswered question. A single 600 mg dose worked through week 4; if antibody levels wane before the month is out, the “monthly dosing” claim — the core differentiator — weakens, and the Phase 2b/3 dose-ranging design exists precisely because the company doesn’t know the answer yet.
2. Immunogenicity: a therapeutic antibody dosed monthly for years in an otherwise-healthy menopausal population is exactly where anti-drug antibodies show up. Any immunogenicity signal in the extension data is a franchise-level problem.
3. Elinzanetant approval plus a Veozah label expansion could crowd the space with two marketed orals before ABCL635 files, compressing the pricing argument for a fourth-to-market (behind hormone therapy and two orals) entrant.
4. AbCellera’s platform economics: ABCL635 is one internal program among many partnered deals, and the stock’s move reflects a company still proving it can drive its own assets to registration, not just discover antibodies for partners.

The position read: this is a Phase 2 data pop in a company with a real platform and one new clinical thesis. The volume says momentum is in control short-term; the disciplined trade sizes for the gap between today’s $9.34 and what a Phase 2b/3 design actually shows, and lets the dose-ranging readout do the valuing.

Source: AbCellera press release, August 10, 2026 · ABCL635 Phase 2 on ClinicalTrials.gov (NCT07118891)